SSSakurako Suma

Sakurako Suma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sakurako Suma has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A multi-center, single-arm, phase 2 trial of dasatinib in T follicular helper cell lymphomas

    by Sakurako Suma, Mamiko Sakata-Yanagimoto, Yasuhito Suehara, Takahide Ara, Hideki Goto, Kensuke Usuki, Koji Izutsu, Motoko Yamaguchi, Noriko Fukuhara, Emiko Sakaida, et al.

  • Pathological Diagnosis of Nodal T Follicular Helper Cell Lymphoma, Angioimmunoblastic Type

    by Naoya Nakamura, Yara Yukie Kikuti, Joaquim Carreras, Ryota Matsuoka, Daisuke Matsubara, Sakurako Suma, Mamiko Sakata‐Yanagimoto, Yohei Masugi

    We herein review the pathological diagnosis of nodal T follicular helper (TFH) cell lymphoma, angioimmunoblastic type (nTFHL‐AI), a mature T‐cell neoplasm with a TFH phenotype that was previously designated as angioimmunoblastic T‐cell lymphoma (AITL). The history of AITL from its discovery to the WHO 5th classification, which includes Japanese pathologists' and hematologists' contributions, is discussed. We then focus on what true neoplastic T cells of nTFHL‐Al are in histopathology. Since the number of neoplastic cells is small in some cases of nTFHL‐AI, the findings of recent single‐cell analyses to immunohistochemistry of TFH markers are considered. We also discuss Epstein–Barr virus large B‐cells in AITL, particularly diffuse large B‐cell lymphoma and classic Hodgkin lymphoma (CHL), and propose how to make a differential diagnosis between nTFHL‐Al and CHL.

  • Open Access

    Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at single-cell resolution

    by Sakurako Suma, Yasuhito Suehara, Manabu Fujisawa, Yoshiaki Abe, Keiichiro Hattori, Kenichi Makishima, Tatsuhiro Sakamoto, Aya Sawa, Hiroko Bando, Daisuke Kaji, et al.

    T follicular helper (TFH) cell lymphomas (TFHLs) are characterized by TFH-like properties and accompanied by substantial immune-cell infiltration into tumor tissues. Nevertheless, the comprehensive understanding of tumor-cell heterogeneity and immune profiles of TFHL remains elusive. To address this, we conducted single-cell transcriptomic analysis on 9 lymph node (LN) and 16 peripheral blood (PB) samples from TFHL patients. Tumor cells were divided into 5 distinct subclusters, with significant heterogeneity observed in the expression levels of TFH markers. Copy number variation (CNV) and trajectory analyses indicated that the accumulation of CNVs, together with gene mutations, may drive the clonal evolution of tumor cells towards TFH-like and cell proliferation phenotypes. Additionally, we identified a novel tumor-cell-specific marker, PLS3. Notably, we found a significant increase in exhausted CD8+ T cells with oligoclonal expansion in TFHL LNs and PB, along with distinctive immune evasion characteristics exhibited by infiltrating regulatory T, myeloid, B, and natural killer cells. Finally, in-silico and spatial cell-cell interaction analyses revealed complex networking between tumor and immune cells, driving the formation of an immunosuppressive microenvironment. These findings highlight the remarkable tumor-cell heterogeneity and immunoevasion in TFHL beyond previous expectations, suggesting potential roles in treatment resistance.


  • Open Access

    Distinct Minor Neoplastic Follicular T-Cell Subsets Dictate Lymphoma Fates through Functional Specialization

    by Yoshiaki Abe, Junko Zenkoh, Daisuke Ikeda, Sawa Aya, Daisuke Kaji, Rikako Tabata, Ryota Matsuoka, Manabu Fujisawa, Kenichi Makishima, Sakurako Suma, et al.

    Disclosures. Yoshida:Bristol Myers Squibb: Research Funding; Novartis Pharmaceuticals: Honoraria. Matsue:AstraZeneca: Research Funding. Chiba:Eisai Co., Ltd.: H

  • Open Access

    Investigation of Clonal Hematopoiesis in New Japanese Cohort

    by Kenichi Makishima, Kashima Yukie, Yuta Kuze, Sakurako Suma, Yoshiaki Abe, Yasuhito Suehara, Tatsuhiro Sakamoto, Keiichiro Hattori, Sakura Kito, Tran Bich Nguyen, et al.

    Disclosures. Chiba:Eisai Co., Ltd.: Honoraria; Bayer Pharma: Honoraria; Chugai Pharmaceutical: Honoraria; Kyowa Kirin: Research Funding; Astellas: Research Fund

  • Open Access

    S237: THE GENETIC SUBTYPES AND THE TUMOR MICROENVIRONMENT SIGNATURES ARE ASSOCIATED WITH DISTINCT OUTCOMES IN PERIPHERAL T-CELL LYMPHOMA

    by Yasuhito Suehara, Kana Sakamoto, Manabu Fujisawa, Kota Fukumoto, Yoshiaki Abe, Kenichi Makishima, Sakurako Suma, Takeshi Sugio, Koji Kato, Koichi Akashi, et al.

  • Open Access

    Clonal germinal center B cells function as a niche for T-cell lymphoma

    by Manabu Fujisawa, Tran B. Nguyen, Yoshiaki Abe, Yasuhito Suehara, Kota Fukumoto, Sakurako Suma, Kenichi Makishima, Chihiro Kaneko, Yen T.M. Nguyen, Kensuke Usuki, et al.

    Angioimmunoblastic T-cell lymphoma (AITL) is proposed to be initiated by age-related clonal hematopoiesis (ACH) with TET2 mutations, whereas the G17V RHOA mutation in immature cells with TET2 mutations promotes the development of T follicular helper (TFH)-like tumor cells. Here, we investigated the mechanism by which TET2-mutant immune cells enable AITL development using mouse models and human samples. Among the 2 mouse models, mice lacking Tet2 in all the blood cells (Mx-Cre × Tet2flox/flox × G17V RHOA transgenic mice) spontaneously developed AITL for approximately up to a year, while mice lacking Tet2 only in the T cells (Cd4-Cre × Tet2flox/flox × G17V RHOA transgenic mice) did not. Therefore, Tet2-deficient immune cells function as a niche for AITL development. Single-cell RNA-sequencing (scRNA-seq) of >50 000 cells from mouse and human AITL samples revealed significant expansion of aberrant B cells, exhibiting properties of activating light zone (LZ)-like and proliferative dark zone (DZ)-like germinal center B (GCB) cells. The GCB cells in AITL clonally evolved with recurrent mutations in genes related to core histones. In silico network analysis using scRNA-seq data identified Cd40–Cd40lg as a possible mediator of GCB and tumor cell cluster interactions. Treatment of AITL model mice with anti-Cd40lg inhibitory antibody prolonged survival. The genes expressed in aberrantly expanded GCB cells in murine tumors were also broadly expressed in the B-lineage cells of TET2-mutant human AITL. Therefore, ACH-derived GCB cells could undergo independent clonal evolution and support the tumorigenesis in AITL via the CD40–CD40LG axis.


  • VAV1 mutations contribute to development of T-cell neoplasms in mice

    by Kota Fukumoto, Mamiko Sakata-Yanagimoto, Manabu Fujisawa, Tatsuhiro Sakamoto, Hiroaki Miyoshi, Yasuhito Suehara, Tran B. Nguyen, Sakurako Suma, Shintaro Yanagimoto, Yuichi Shiraishi, et al.

    Activating mutations in the Vav guanine nucleotide exchange factor 1 (VAV1) gene are reported in various subtypes of mature T-cell neoplasms (TCNs). However, oncogenic activities associated with VAV1 mutations in TCNs remain unclear. To define them, we established transgenic mice expressing VAV1 mutants cloned from human TCNs. Although we observed no tumors in these mice for up to a year, tumors did develop in comparably aged mice on a p53-null background (p53−/−VAV1-Tg), and p53−/−VAV1-Tg mice died with shorter latencies than did p53-null (p53−/−) mice. Notably, various TCNs with tendency of maturation developed in p53−/−VAV1-Tg mice, whereas p53−/− mice exhibited only immature TCNs. Mature TCNs in p53−/−VAV1-Tg mice mimicked a subtype of human peripheral T-cell lymphoma (PTCL-GATA3) and exhibited features of type 2 T helper (Th2) cells. Phenotypes seen following transplantation of either p53−/−VAV1 or p53−/− tumor cells into nude mice were comparable, indicating cell-autonomous tumor-initiating capacity. Whole-transcriptome analysis showed enrichment of multiple Myc-related pathways in TCNs from p53−/−VAV1-Tg mice relative to p53−/− or wild-type T cells. Remarkably, amplification of the Myc locus was found recurrently in TCNs of p53−/−VAV1-Tg mice. Finally, treatment of nude mice transplanted with p53−/−VAV1-Tg tumor cells with JQ1, a bromodomain inhibitor that targets the Myc pathway, prolonged survival of mice. We conclude that VAV1 mutations function in malignant transformation of T cells in vivo and that VAV1-mutant–expressing mice could provide an efficient tool for screening new therapeutic targets in TCNs harboring these mutations.